Michael Halstead Biography and Net Worth



Mr. Halstead has been the General Counsel of ITCI since July 2014. From July 2005 until December 2013, Mr. Halstead served in a number of leadership positions at Warner Chilcott plc, a leading specialty pharmaceutical company that was acquired by Actavis plc in October 2013. Most recently, he was Senior Vice President, Corporate Development at Warner Chilcott, where he directed the company’s corporate development, legal, and human resources functions. Prior to that, Mr. Halstead was an attorney at Davis Polk & Wardwell, where he focused his practice on mergers and acquisitions, corporate governance, and securities law compliance.

Mr. Halstead received his bachelor’s degree from Boston University and his Juris Doctor degree from Villanova University School of Law.

What is Michael Halstead's net worth?

The estimated net worth of Michael Halstead is at least $1.49 million as of March 11th, 2024. Mr. Halstead owns 19,803 shares of Intra-Cellular Therapies stock worth more than $1,494,730 as of June 19th. This net worth estimate does not reflect any other investments that Mr. Halstead may own. Additionally, Mr. Halstead receives a salary of $983,650.00 as EVP at Intra-Cellular Therapies. Learn More about Michael Halstead's net worth.

How old is Michael Halstead?

Mr. Halstead is currently 51 years old. There are 6 older executives and no younger executives at Intra-Cellular Therapies. The oldest executive at Intra-Cellular Therapies is Dr. Robert E. Davis Ph.D., Senior VP & Chief Scientific Officer, who is 73 years old. Learn More on Michael Halstead's age.

What is Michael Halstead's salary?

As the EVP of Intra-Cellular Therapies, Inc., Mr. Halstead earns $983,650.00 per year. There are 2 executives that earn more than Mr. Halstead. The highest earning executive at Intra-Cellular Therapies is Dr. Sharon Mates Ph.D., Co-Founder, Chairman & CEO, who commands a salary of $2,230,000.00 per year. Learn More on Michael Halstead's salary.

How do I contact Michael Halstead?

The corporate mailing address for Mr. Halstead and other Intra-Cellular Therapies executives is 430 EAST 29TH STREET, NEW YORK NY, 10016. Intra-Cellular Therapies can also be reached via phone at (464) 440-9333 and via email at [email protected]. Learn More on Michael Halstead's contact information.

Has Michael Halstead been buying or selling shares of Intra-Cellular Therapies?

Michael Halstead has not been actively trading shares of Intra-Cellular Therapies during the past quarter. Most recently, Michael Halstead sold 7,345 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $65.97, for a transaction totalling $484,549.65. Following the completion of the sale, the executive vice president now directly owns 19,803 shares of the company's stock, valued at $1,306,403.91. Learn More on Michael Halstead's trading history.

Who are Intra-Cellular Therapies' active insiders?

Intra-Cellular Therapies' insider roster includes Christopher Alafi (Director), Suresh Durgam (Insider), Michael Halstead (EVP), Lawrence Hineline (CFO), Joel Marcus (Director), Sharon Mates (CEO), Mark Neumann (EVP), Rory Riggs (Director), and Robert Van Nostrand (Director). Learn More on Intra-Cellular Therapies' active insiders.

Are insiders buying or selling shares of Intra-Cellular Therapies?

During the last year, insiders at the biopharmaceutical company sold shares 19 times. They sold a total of 600,431 shares worth more than $38,698,622.81. The most recent insider tranaction occured on March, 11th when CEO Sharon Mates sold 20,565 shares worth more than $1,341,043.65. Insiders at Intra-Cellular Therapies own 3.4% of the company. Learn More about insider trades at Intra-Cellular Therapies.

Information on this page was last updated on 3/11/2024.

Michael Halstead Insider Trading History at Intra-Cellular Therapies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/11/2024Sell7,345$65.97$484,549.6519,803View SEC Filing Icon  
2/26/2024Sell7,907$69.53$549,773.7129,700View SEC Filing Icon  
1/11/2024Sell50,000$66.83$3,341,500.00View SEC Filing Icon  
12/1/2022Sell50,000$53.73$2,686,500.00View SEC Filing Icon  
12/21/2021Sell176,863$47.56$8,411,604.28View SEC Filing Icon  
1/4/2021Sell16,160$31.30$505,808.00
11/17/2020Sell79,425$27.62$2,193,718.5079,425View SEC Filing Icon  
1/6/2020Sell21,458$30.34$651,035.7217,704View SEC Filing Icon  
1/2/2020Sell7,807$32.43$253,181.017,998View SEC Filing Icon  
1/7/2019Sell3,108$12.42$38,601.3624,757View SEC Filing Icon  
1/4/2019Sell21,458$11.46$245,908.6824,757View SEC Filing Icon  
1/22/2018Sell25,500$18.03$459,765.00191View SEC Filing Icon  
1/5/2017Sell1,601$16.55$26,496.5521,506View SEC Filing Icon  
11/6/2014Buy20,000$15.38$307,600.00View SEC Filing Icon  
See Full Table

Michael Halstead Buying and Selling Activity at Intra-Cellular Therapies

This chart shows Michael Halstead's buying and selling at Intra-Cellular Therapies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Intra-Cellular Therapies Company Overview

Intra-Cellular Therapies logo
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Read More

Today's Range

Now: $75.48
Low: $71.56
High: $78.53

50 Day Range

MA: $69.00
Low: $64.76
High: $79.84

2 Week Range

Now: $75.48
Low: $45.50
High: $84.89

Volume

4,706,601 shs

Average Volume

656,398 shs

Market Capitalization

$7.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97